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influence of MC-1R variants and pigmen-
ted skin on UVR-blood flow dose-
response (Young et al., 1985; Flanagan
et al., 2001). In view of an encouraging
report, we also explored the possibility of
using a* (‘redness’), a hemoglobin (Hb)
index, and Hb oxygen (HbO2) saturation
gained with a standard spectrophoto-
meter (CM-600D; Konica Minolta) to
describe erythemal responses (Kollias
et al., 1994). However, we found that
they by no means reached the level of
reliability of the MFD in assessing
minimal sunburn in pigmented skin
(Supplementary Figure 1a–d online).
MFD permits objective assessment
of UVR-vasodilatation response, which
is transferable between laboratories.
Although our data suggest that 30% flux
increase is a good threshold for MFD,
this should be verified in a larger study
with more extensive MED and MFD
assessments. Laser speckle contrast ima-
ging appears to be more sensitive and
more reliable compared with other
available objective methods, such as
determining oxyhemoglobin levels from
reflectance spectra. Hence, we find
785 nm laser speckle contrast imaging
excellently suited to assess robustly a
minimal sunburn reaction (by vasodila-
tation) even in heavily pigmented skin.
Influence of skin pigmentation on UVR
responses is an area of substantial cur-
rent interest and controversy (Brenner
and Hearing, 2008; Bogh et al., 2010;
Farrar et al., 2011), and this technique
will assist its further exploration.
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TO THE EDITOR
Se´zary syndrome (SS) is an aggressive
cutaneous T-cell lymphoma charac-
terized by high numbers of neoplastic
T cells in peripheral blood, lymph nodes,
and skin. Optimal therapy is challenging
and prognosis is poor with an overall
5-year survival of around 25%.
Alemtuzumab is a humanized IgG1
mAb directed against the CD52 antigen,
a 21–28 kDa cell surface glycoprotein
attached to the cell membrane by
a glycosylphosphatidyl-inositol (GPI)
anchor. CD52 is expressed on T and B
lymphocytes, natural killer cells, mono-
cytes, and some dendritic cells. In vitro
studies showed that alemtuzumab inducesAccepted article preview online 28 November 2014; published online 8 January 2015
Abbreviations: GPI, glycosylphosphatidyl-inositol; PNH, paroxysmal nocturnal hemoglobinuria; SCT, stem
cell transplantation; SS, Se´zary syndrome
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complement- and antibody-dependent
cellular cytotoxicity of CD52-expre-
ssing cells, and several studies showed
that alemtuzumab can be effective
in the treatment of T-cell lymphomas
and leukemias, including SS (Bernengo
et al., 2007; Alinari et al., 2008;
Querfeld et al., 2009; De Masson
et al., 2014).
We describe a patient with SS who
initially responded to alemtuzumab
treatment but then developed progres-
sive disease. Molecular studies demon-
strated that, with progression, the tumor
cells lost expression of CD52, which
was the result of a truncating splice site
mutation in the PIGA (phosphatidylino-
sitolglycan class A) gene, encoding one
of the proteins essential for biosynthesis
of the GPI anchor.
A 68-year-old man was referred to
us with a 10-year history of a diffuse
pruritic erythroderma with multiple
excoriations and lichenification, treated
with PUVA, UVB, and local and systemic
corticosteroids. Laboratory investiga-
tions showed leukocytosis (leukocyte
count 28.4109 l1) and lymphocyto-
sis (lymphocyte count 12.8 109 l1)
with 12287 106 CD4þ cells per l
and 211106 CD8þ cells per l,
resulting in a CD4:CD8 ratio of 58.
Molecular analysis of peripheral blood
demonstrated T-cell clonality. com-
puted tomography scan of the thorax
and abdomen showed no lymphadeno-
pathy. Skin histology showed a perivas-
cular infiltrate of atypical T cells that
expressed CD2, CD3, CD5, and CD4
but did not stain for CD8. A diagnosis of
SS was made and treatment was started
with local and systemic treatment,
including prednisone 30 mg and chlor-
ambucil 4 mg daily. However, his skin
symptoms gradually worsened, and, 6
months after presentation at our
hospital, treatment was switched to sub-
cutaneous alemtuzumab (10 mg). This
resulted in a greatly reduced number of
circulating tumor cells and rapid impro-
vement of skin symptoms (Figure 1).
During follow-up, alemtuzumab treat-
ment was repeated when CD4þ counts
exceeded 1000106 l 1, every time
with excellent results. However, 7
months after starting alemtuzumab, no
more treatment effects were observed
and the number of circulating atypical T
cells was seen to have greatly increased
and his skin symptoms had relapsed
(Figure 1). After treatment with cyclo-
phosphamide, hydroxydaunorubicin,
oncovin, prednisone chemotherapy
(5 ), a nonmyeloablative stem cell
transplantation (alloSCT) with a mat-
ched unrelated donor was performed.
Unfortunately, he developed a systemic
anaplastic lymphoma kinase–negative
anaplastic large cell lymphoma 2
months after the alloSCT and died of
progressive disease.
Previous studies showed that alemtu-
zumab is an effective treatment in
patients with cutaneous T-cell lympho-
mas, particularly SS. However, these
studies also noted that a minority of SS
cases are refractory to alemtuzumab
treatment, and in one patient resistance
was linked to lower expression levels of
CD52 (Fernandes et al., 2012). In our
patient we observed that a small
minority (0.1%) of GPI- and CD52-
tumor cells (CD3þ , CD4þ , and
CD7 ) were already present before
alemtuzumab treatment and that under
alemtuzumab treatment this GPI- and
CD52- subpopulation expanded to 97%
of CD4þ T cells (Figure 1). Before
treatment, 41% of the Se´zary cells
had a naive phenotype (CD45RAþ ,
CD27þ ) and 32% had a memory phe-
notype (CD45ROþ ). At the time of
relapse, 12% of the CD52-negative
Se´zary cells had a naive phenotype
and 76% had a memory phenotype
and showed coexpression of CCR7 and
CD28. Similarly, appearance of CD52-
negative T cells and B cells under
treatment with alemtuzumab has been
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Figure 1. Effect of alanine aminotransferase (ALT) treatment on CD52þ Se´zary syndrome (SS) cells and ultimate formation of disease relapse caused by
CD52 , glycosylphosphatidyl-inositol (GPI) anchor defective SS cells escaping from ALT treatment. The patient was treated with 10 mg ALT subcutaneously
(s.c.) for his CD52þ SS at different time points (D, first infusion was 3 mg s.c. (D)). On the primary y-axis we plotted the absolute numbers of CD52þ SS cells
in peripheral blood at different days after first ALT treatment (black line). After initial disease control the patient relapsed. This disease relapse was no longer
responding to ALT treatment because of the absence of CD52 expression on the recurring SS cells, caused by loss of GPI anchor expression as determined
by staining with Alexa Fluor 488–labeled fluorescent aerolysin (FLAER). On the secondary y-axis we plotted the absolute number of CD52-/FLAER- SS cells
at different days after first ALT treatment (gray line). On day 280 after the first ALT treatment cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone
treatment was started ( ).
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described in rheumatoid arthritis (Brett
et al., 1996), and development of
CD52-negative tumor cells under alem-
tuzumab treatment was described in
chronic lymphocytic leukemia (Rawstron
et al., 1999), B-cell non-Hodgkin’s lym-
phoma (Hertenstein et al., 1995), and
T-cell prolymphocytic leukemia (Tuset
et al., 2001). In some of these studies,
CD52-negative cells were also found to
be defective in the expression of other
GPI-anchored proteins like CD55 and
CD59, thereby closely resembling the
phenotype of lymphocytes from patients
with paroxysmal nocturnal hemoglo-
binuria (PNH). In this acquired clonal
stem cell disorder, an increased suscep-
tibility of erythrocytes to autologous
complement is observed, which is due
to a defective expression of GPI-anchored,
complement-inhibitory proteins. GPI
expression can be measured using
fluorescent aerolysin staining. In PNH
patients this absence of GPI-anchored
proteins is the result of a defect in the
first-step GPI anchor biosysnthesis due
to a mutation in the PIGA gene located
on chromosome Xp22.1.
To explore the underlying molecular
mechanism of the observed CD52 loss
in this patient, we investigated CD52
and GPI anchor biosynthesis in more
detail. First we analyzed gene expres-
sion for CD52 and for the genes that are
essential for GPI anchor biosynthesis—
namely, DPM2, PIGA, PIGC, PIGH,
PIGL, PIGM, PIGP, and PIGY—in flow-
sorted subpopulations of CD52-positive
and CD52-negative tumor cells using
quantitative PCR (data not shown).
These studies revealed a significant loss
of PIGA and gain of PIGY expression in
CD52-negative tumor cells. Mutational
analysis of CD52-negative cells showed
a mutation (GT -GG) in the 5’ intron
Splice Site Consensus, of intron 2
belonging to transcript variant 1
(NM_002641.3) of the PIGA gene
(Figure 2a). Alternative splicing in which
intron 2 (B5.5 Kb) is retained in the
transcript then leads to the introduction
of premature termination codons, which
can induce nonsense-mediated decay.
In sorted CD52-negative tumor cells,
containing this particular mutation,
expression of solely PIGA non-coding
transcript variants 4 (NR_033835.1) and
5 (NR_033836.1) was observed, suggest-
ing the decay of the coding variant 1
(Figure 2b). In addition, we investigated
whether promoter hypermethylation of
PIGA could contribute to the loss of
PIGA expression, but methylation-speci-
fic melting curve analysis showed no
methylation of the promoter-located
CpG island (data not shown).
This study shows that a small minority
of CD52-negative tumor cells can
already be observed in alemtuzumab-
naive patients with SS and that under
alemtuzumab treatment this escape
variant can expand, ultimately leading
to progression of disease and treatment
failure. Mutations in the PIGA gene
leading to the loss of GPI expression
are frequently observed, even in healthy
people (Ware et al., 2001). The expan-
ded clone of GPI-deficient Se´zary cells
might have developed from a subclone
of Se´zary cells that already harbored this
mutation at the start of alemtuzumab
treatment, or, alternatively, might have
occurred during alemtuzumab treat-
ment. Likewise, we are not able to
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Figure 2. Results of sequencing and transcription analysis of PIGA in CD52þ and CD52 flow cytometry–sorted tumor cells. (a) Sanger sequencing results of
genomic DNA originated from CD52þ (left) and CD52– tumor cells (right). Sequences represent the splice site region between the 30 end of exon 2 and 50 start
of intron 2 of PIGA (HGNC: 8957). Boxed nucleotides represent the most relevant bases of the 50 intron splice site consensus. CD52– tumor cells contain a
homozygous mutation in this site (IVS2þ 2T4G). (b) Schematic depiction of the PIGA gene as located on chromosome X. Arrows indicate direction of
transcription where small boxes represent non-coding exonic sequences and large boxes represent coding regions. Observed PIGA transcripts in CD52þ tumor
cells (left) include the coding variant 1 (NM_002641.3), whereas CD52 tumor cells (right), containing the IVS2þ 2T4G splice site mutation, consist only of
non-coding variants.
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determine whether previous treatment
with alemtuzumab had a role in the
development of the systemic anaplastic
lymphoma kinase-negative anaplastic
large cell lymphoma after alloSCT.
On the basis of this observation we
recommend the monitoring of fluores-
cent aerolysin and CD52 expression
under alemtuzumab treatment. Further-
more, investigations on strategies that
prevent the outgrowth of the CD52-
negative subpopulation under alemtu-
zumab treatment are clearly needed.
An intriguing possibility is that CD52-
negative SS cells are more vulnerable
to complement-mediated cell lysis
because of the reduced expression of
complement-inhibitory proteins such
as CD55 and CD59 that, similar to
CD52, require GPI-anchored proteins
for their membrane expression.
Consequently, these SS cells might be
still sensitive (or even more vulnerable)
to treatment with other tumor cell–
directed antibodies (such as anti-CD4
and anti-CCR4 antibodies), as was
recently described in one patient
(Alexandroff et al., 2011).
The described patient provided writ-
ten informed consent for this study.
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